SEEDING OF INTRAVASCULAR STENTS WITH GENETICALLY ENGINEERED ENDOTHELIAL CELLS

支架被用作临床设备以维持有效的 血管结构内的内部支架。然而，最终的效用 支架植入的早期和晚期不良生物学特性可能限制支架植入的成功率。 应答支架置入后的亚急性血栓性闭合， 新生内膜增生在某些情况下会导致不良的临床结果， 患者为了提高支架的多功能性和功能， 分子生物学技术被认为是减少表面 血栓形成性，并引起更有利的生物反应。由于动物 研究表明快速支架内皮化显著降低了 早期血栓形成，本研究是为了植入金属支架 用基因工程内皮细胞， 细菌β-半乳糖苷酶或人组织纤溶酶原激活剂。 这项工作是在与联合国秘书长的密切合作下监督和执行的。 分子血液学分支指出， 工程化内皮细胞确实可行。这些初步 研究结果表明，支架表面的修饰 部分或全部内皮细胞覆盖可能导致 不易形成血栓的环境， 局部递送药物物质， 支架功能。

Stents are being used as a clinical device to maintain an effective internal scaffold within vascular structures. However, the ultimate utility of stent implantation maybe limited by adverse early and late biological responses. Both subacute thrombotic closure after stent placement and neointimal proliferation have resulted in untoward clinical results in some patients. In an effort to improve versatility and function of stents molecular biology techniques are being considered to reduce surface thrombogenicity and evoke more favorable biological responses. Since animal studies have indicated that rapid stent endothelialization markedly reduces early thrombus formation, this study was undertaken to seed metallic stents with genetically engineered endothelial cells incorporating the gene for either bacterial B-galactosidase or human tissue plasminogen activator. This work, supervised and performed in close collaboration with the Molecular Hematology Branch, indicated that seeding stents with genetically engineered endothelial cells was indeed feasible. These preliminary findings suggest the possibility that modification of the stent surface with partial or complete endothelial cell coverage might result in an environment less susceptible to thrombus formation with the potential for local delivery of pharmacologic substances which might ultimately improve stent function.